Recombinant Bicomponent COVID-19 Vaccine (Jiangsu Recbio Technology)

้‡็ป„ๅŒ็ป„ๅˆ†ๆ–ฐๅ† ็–ซ่‹— (ๆฑŸ่‹็‘ž็ง‘็”Ÿ็‰ฉ)

Report date: 2026/04/03 20:03:44

Base Information

Drug NameRecombinant Bicomponent COVID-19 Vaccine (Jiangsu Recbio Technology)
Drug Alias NameReCOV้‡็ป„ๅŒ็ป„ๅˆ†ๆ–ฐๅ† ็—…ๆฏ’็–ซ่‹— (ๆฑŸ่‹็‘ž็ง‘็”Ÿ็‰ฉ)Recombinant two-component COVID-19 vaccine (CHO cell) (Jiangsu Rec-Biotechnology)Recombinant Bicomponent COVID-19 Vaccine (BFA03)็‘žๅคๆณฐ
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPhilippinesNew ZealandNepal +[5]ย 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesJiangsu Rec-Biotechnology Co LtdInstitute Of Biophysics, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Rec-Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A